Loading clinical trials...
Loading clinical trials...
Possible Role of Coenzyme Q10 in Prevention of Contrast Induced Nephropathy in Patients With Acute Coronary Syndrome Undergoing Coronary Angiography With or Without Intervention.
In this study the investigators aim to study the effect of supplementation of CoQ10 in decreasing the incidence of contrast induced acute kidney injury in patients with acute coronary syndrome undergoing coronary angiography.
Patients who fulfilled the inclusion criteria and agreed to participate in the study will be randomly divided into 2 groups using their computer generated random numbers that group a will receive the coenzyme Q10 in addition to the standard preventive measures and group b will receive only the standard preventive measures without the coenzyme Q10.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Ain Shams university hospitals
Cairo, Egypt
Ramy Mohamed Mostafa
Cairo, Egypt
Start Date
June 15, 2024
Primary Completion Date
October 1, 2024
Completion Date
November 1, 2024
Last Updated
June 28, 2024
250
ESTIMATED participants
Coenzyme Q10 100 Milligrams Oral Capsule
DRUG
Placebo
DRUG
Lead Sponsor
Ain Shams University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04606056